New Botox Rival Reloxin May Cost Less and Be Safer
A new anti-wrinkle drug called Reloxin may soon push Botox to the wayside, and studies are showing that it isn’t just a safe alternative, but an improvement that could save you money.
Reloxin is currently used in 23 other countries and also has a 15-year history outside America in treating neurological disorders. But, the drug is still pending approval from the Food and Drug Administration here in the United States.
The Moy-Fincher Medical Group in Los Angeles recently released the results of a study in which Reloxin was tested on a group of 1,200 adults.
The researchers found that up to 95 percent of patients showed noticeable improvement within seven days, and reported no long-term safety issues. The drug is a development of the French company Ipsen, and it uses the same principle as Botox, which is that it prevents facial muscles from contracting and causing skin wrinkles.
But unlike Botox, it breaks down slowly enough in the body to give results that can last more than a year, whereas the effects of Botox last only a few months. The lasting results of Reloxin reportedly are due to lesser amounts of both protein and antigens. Reloxin is also reported to spread throughout the tissue better than Botox, which makes it well-suited for areas such as the forehead.
Perhaps most importantly, the cost of one vial of Reloxin is about 15 percent less than Botox, not to mention the fact that patients will need treatment less often.
The FDA is expected to approve the drug later this month.